GPR50 and cancer: Based on genomic profiling and differential expression analyses of 198 and 520 esophageal carcinoma and head-and-neck squamous cell carcinoma (HNSC) samples from The Cancer Genome Atlas and Cancer Cell Line Encyclopedia, upregulation of GPR50, which inhibits the MT1 receptor through heterodimerization, was found to be significantly associated with poor survival.